普利制药
(300630)
| 流通市值：49.63亿 | | | 总市值：66.28亿 |
| 流通股本：3.38亿 | | | 总股本：4.52亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,352,234,193.69 | 834,040,351.84 | 373,166,292.2 | 1,806,344,586.37 |
| 营业收入 | 1,352,234,193.69 | 834,040,351.84 | 373,166,292.2 | 1,806,344,586.37 |
| 二、营业总成本 | 968,931,149.46 | 585,355,540.06 | 243,515,781.3 | 1,382,121,378.45 |
| 营业成本 | 437,659,600.24 | 253,101,465.99 | 104,661,902.17 | 616,960,633.45 |
| 税金及附加 | 5,745,697.52 | 4,582,015.66 | 2,374,980.84 | 12,208,109.66 |
| 销售费用 | 179,676,497.83 | 127,322,213.03 | 51,140,496.07 | 350,653,645.98 |
| 管理费用 | 88,470,352.09 | 53,490,768.28 | 15,061,173.01 | 107,318,647.48 |
| 研发费用 | 229,840,778.19 | 131,718,705.5 | 61,517,923.07 | 263,038,459.28 |
| 财务费用 | 27,538,223.59 | 15,140,371.6 | 8,759,306.14 | 31,941,882.6 |
| 其中:利息费用 | 33,143,542.38 | 20,883,513.53 | - | 40,151,598.42 |
| 其中:利息收入 | 4,155,070.97 | 3,583,872.06 | - | 4,926,767.91 |
| 加:公允价值变动收益 | - | - | - | -94,443.18 |
| 加:投资收益 | 4,540,678.13 | 3,134,905.75 | 2,463,766.47 | -1,401,882.82 |
| 资产减值损失(新) | -601,616.75 | -601,616.75 | - | - |
| 信用减值损失(新) | -34,168,528.95 | -10,054,668.9 | -1,694,678.65 | -9,255,484.08 |
| 其他收益 | 57,916,312.67 | 36,854,869.18 | 9,070,325.65 | 26,030,482.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 410,989,889.33 | 278,018,301.06 | 139,489,924.37 | 439,501,880.08 |
| 加:营业外收入 | 140,575.35 | 101,868.78 | 19,399.77 | 173,571.22 |
| 减:营业外支出 | 192,862.35 | 14,947.89 | 82.03 | 758,939.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 410,937,602.33 | 278,105,221.95 | 139,509,242.11 | 438,916,511.65 |
| 减:所得税费用 | 6,637,302.01 | 8,159,662 | 1,076,155.7 | 18,300,804.01 |
| 六、净利润 | 404,300,300.32 | 269,945,559.95 | 138,433,086.41 | 420,615,707.64 |
| 持续经营净利润 | 404,300,300.32 | 269,945,559.95 | 138,433,086.41 | 420,615,707.64 |
| 归属于母公司股东的净利润 | 404,300,300.32 | 269,945,559.95 | 138,433,086.41 | 420,615,707.64 |
| (一)基本每股收益 | 0.93 | 0.62 | 0.32 | 0.96 |
| (二)稀释每股收益 | 0.84 | 0.56 | 0.32 | 0.9 |
| 九、综合收益总额 | 404,300,300.32 | 269,945,559.95 | 138,433,086.41 | 420,615,707.64 |
| 归属于母公司股东的综合收益总额 | 404,300,300.32 | 269,945,559.95 | 138,433,086.41 | 420,615,707.64 |
| 公告日期 | 2023-10-25 | 2023-08-25 | 2023-04-25 | 2023-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |